This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.


Eisai Co., Ltd.

Drug Names(s): GPI 15715, fospropofol disodium, E2083, Aquavan

Description: AQUAVAN is a novel, water-soluble pro-drug of propofol, a commonly used intravenous anesthetic.

Deal Structure: Aquavan was developed by Guilford Pharmaceuticals. On October 3, 2005, MGI PHARMA closed its previously-announced acquisition of Guilford.

In December 2007, Eisai and MGI Pharma announced that they entered into a definitive merger agreement under which Eisai would acquire all of the outstanding shares of MGI Pharma for US$41.00 per share in an all cash transaction, for a total consideration of approximately $3.9 billion.

Partners: ProQuest Pharmaceuticals Inc.

Lusedra News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug